Dashboard
1
With a growth in Net Profit of 336.33%, the company declared Outstanding results in Sep 25
- The company has declared positive results in Jan 70 after 14 consecutive negative quarters
- RAW MATERIAL COST(Y) Fallen by -79.52% (YoY)
- NET SALES(Q) Highest at CNY 254.65 MM
- OPERATING PROFIT(Q) Highest at CNY 33.34 MM
2
With ROE of 0.91%, it has a fair valuation with a 1.89 Price to Book Value
3
Market Beating Performance
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.7%
0%
-11.7%
6 Months
-10.49%
0%
-10.49%
1 Year
49.49%
0%
49.49%
2 Years
39.61%
0%
39.61%
3 Years
-0.94%
0%
-0.94%
4 Years
-18.37%
0%
-18.37%
5 Years
0%
0%
0.0%
Tongling Jieya Biologic Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-12.04%
EBIT Growth (5y)
-40.63%
EBIT to Interest (avg)
30.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.74
Sales to Capital Employed (avg)
0.31
Tax Ratio
13.20%
Dividend Payout Ratio
29.77%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.50%
ROE (avg)
5.62%
Valuation key factors
Factor
Value
P/E Ratio
208
Industry P/E
Price to Book Value
1.89
EV to EBIT
541.18
EV to EBITDA
41.98
EV to Capital Employed
3.53
EV to Sales
4.05
PEG Ratio
NA
Dividend Yield
0.14%
ROCE (Latest)
0.65%
ROE (Latest)
0.91%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
254.60
122.90
107.16%
Operating Profit (PBDIT) excl Other Income
33.30
14.90
123.49%
Interest
0.70
0.10
600.00%
Exceptional Items
1.20
3.00
-60.00%
Consolidate Net Profit
35.50
8.10
338.27%
Operating Profit Margin (Excl OI)
130.90%
16.40%
11.45%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 107.16% vs -26.76% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 338.27% vs -71.07% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
545.90
618.10
-11.68%
Operating Profit (PBDIT) excl Other Income
62.70
135.70
-53.80%
Interest
0.90
1.10
-18.18%
Exceptional Items
-12.40
-1.40
-785.71%
Consolidate Net Profit
19.20
114.50
-83.23%
Operating Profit Margin (Excl OI)
27.60%
156.40%
-12.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -11.68% vs -6.90% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -83.23% vs -18.79% in Dec 2023
About Tongling Jieya Biologic Technology Co., Ltd. 
Tongling Jieya Biologic Technology Co., Ltd.
FMCG
No Details Available.
Company Coordinates 
No Company Details Available






